Switch theme
Sign up to access all valuation multiples
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
1983
122
LTM Revenue $148M
LTM EBITDA $8.6M
$412M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Heron Therapeutics has a last 12-month revenue of $148M and a last 12-month EBITDA of $8.6M.
In the most recent fiscal year, Heron Therapeutics achieved revenue of $144M and an EBITDA of -$5.1M.
Heron Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Heron Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $127M | $144M | XXX | XXX | XXX |
| Gross Profit | $52.8M | $61.9M | XXX | XXX | XXX |
| Gross Margin | 42% | 43% | XXX | XXX | XXX |
| EBITDA | -$104M | -$5.1M | XXX | XXX | XXX |
| EBITDA Margin | -82% | -4% | XXX | XXX | XXX |
| Net Profit | -$182M | -$111M | XXX | XXX | XXX |
| Net Margin | -143% | -77% | XXX | XXX | XXX |
| Net Debt | $134M | $145M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Heron Therapeutics's stock price is $2.
Heron Therapeutics has current market cap of $294M, and EV of $412M.
See Heron Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $412M | $294M | XXX | XXX | XXX | XXX | $-0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Heron Therapeutics has market cap of $294M and EV of $412M.
Heron Therapeutics's trades at 2.8x LTM EV/Revenue multiple, and 48.0x LTM EBITDA.
Analysts estimate Heron Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Heron Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $412M | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | -81.6x | XXX | XXX | XXX |
| P/E | -21.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -17.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHeron Therapeutics's NTM/LTM revenue growth is 11%
Heron Therapeutics's revenue per employee for the last fiscal year averaged $1.2M, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Heron Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Heron Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Heron Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -4% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -95% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 8% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 33% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 37% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 81% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Heron Therapeutics acquired XXX companies to date.
Last acquisition by Heron Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Heron Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Heron Therapeutics founded? | Heron Therapeutics was founded in 1983. |
| Where is Heron Therapeutics headquartered? | Heron Therapeutics is headquartered in United States of America. |
| How many employees does Heron Therapeutics have? | As of today, Heron Therapeutics has 122 employees. |
| Who is the CEO of Heron Therapeutics? | Heron Therapeutics's CEO is Mr. Craig A. Collard. |
| Is Heron Therapeutics publicy listed? | Yes, Heron Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Heron Therapeutics? | Heron Therapeutics trades under HRTX ticker. |
| When did Heron Therapeutics go public? | Heron Therapeutics went public in 1987. |
| Who are competitors of Heron Therapeutics? | Similar companies to Heron Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Heron Therapeutics? | Heron Therapeutics's current market cap is $294M |
| What is the current revenue of Heron Therapeutics? | Heron Therapeutics's last 12-month revenue is $148M. |
| What is the current EBITDA of Heron Therapeutics? | Heron Therapeutics's last 12-month EBITDA is $8.6M. |
| What is the current EV/Revenue multiple of Heron Therapeutics? | Current revenue multiple of Heron Therapeutics is 2.8x. |
| What is the current EV/EBITDA multiple of Heron Therapeutics? | Current EBITDA multiple of Heron Therapeutics is 48.0x. |
| What is the current revenue growth of Heron Therapeutics? | Heron Therapeutics revenue growth between 2023 and 2024 was 14%. |
| Is Heron Therapeutics profitable? | Yes, Heron Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
